On May 3, 2023 KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-therapeutic oncolytic viral immunotherapy programs, reported that its Director of Immunology, Ravikumar Muthuswamy, Ph.D., will present "Novel Oncolytic therapy VET3-TGI restricts TGFβ1 and augments Type-1 immune response in TME, leading to superior therapeutic efficacy in multiple preclinical tumor models," an overview of data on its lead pre-clinical candidate, VET3-TGI, in an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting (Press release, KaliVir Immunotherapeutics, MAY 3, 2023, View Source;cell-therapy-asgct-annual-meeting-301813498.html [SID1234630951]). The presentation is on Friday, May 19, 2023 at 5:15 PM PST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

VET3-TGI is based on KaliVir’s unique Vaccinia Enhanced Template (VET) platform, capable of generating potent novel oncolytic vaccinia viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. VET3-TGI incorporates modifications granting the expression of CXCR3, IL-12 and a TGF-β inhibitor, allowing for efficient trafficking to the tumor, activation of anti-tumor immune responses and inhibition of immunosuppressive activity.